We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-22.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$402M
AUM Growth
-$164M
Cap. Flow
+$47.9M
Cap. Flow %
11.9%
Top 10 Hldgs %
62.89%
Holding
86
New
14
Increased
17
Reduced
23
Closed
25
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$55.3M
2
AMRN icon
Amarin Corp
AMRN
+$43M
3
TGTX icon
TG Therapeutics
TGTX
+$21.3M
4
APLS icon
Apellis Pharmaceuticals
APLS
+$20.9M
5
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$15.8M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$21.9M
2
BOLD icon
Audentes Therapeutics, Inc
BOLD
+$18.3M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$16M
4
ENSG icon
The Ensign Group
ENSG
+$14M
5
SNY icon
Sanofi
SNY
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.24%
2 Miscellaneous 5.59%
3 Communication Services 2.07%
4 Financials 0.11%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZGNX
1
DELISTED
Zogenix, Inc.
ZGNX
$49.8M 12.38%
2,013,467
+1,517,822
+306% +$55.3M
2017 Q4
9 quarters
DHR icon
2
Danaher
DHR
$163B
$32.4M 8.06%
263,903
+41,566
+19% +$5.6M
2018 Q3
6 quarters
ASND icon
3
Ascendis Pharma A/S
ASND
$14.9B
$31M 7.71%
275,494
+72,600
+36% +$9.43M
2017 Q4
9 quarters
TGTX icon
4
TG Therapeutics
TGTX
$8.57B
$24.2M 6.02%
2,461,137
+1,684,814
+217% +$21.3M
2018 Q1
8 quarters
APLS icon
5
DELISTED
Apellis Pharmaceuticals
APLS
$24.1M 5.99%
899,474
+589,065
+190% +$20.9M
2018 Q2
7 quarters
CCXI icon
6
DELISTED
ChemoCentryx, Inc.
CCXI
$23.3M 5.79%
580,011
+66,822
+13% +$2.84M
2019 Q4
1 quarter
GSK icon
7
GSK
GSK
$98.2B
$19.9M 4.94%
408,457
-410,011
-50% -$21.9M
2018 Q1
8 quarters
DCPH icon
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$17M 4.24%
414,081
+285,333
+222% +$15.8M
2018 Q4
5 quarters
AZN icon
9
AstraZeneca
AZN
$259B
$15.7M 3.91%
176,276
+105,995
+151% +$9.98M
2019 Q4
1 quarter
SPY icon
10
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$15.5M 3.84%
60,000
-100,000
-63% -$30.5M
2019 Q4
1 quarter
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.05B
$15.1M 3.75%
7,542,372
+2,637,912
+54% +$7.26M
2017 Q4
9 quarters
AMRN icon
12
Amarin Corp
AMRN
$244M
$14M 3.48%
175,203
+129,423
+283% +$43M
2018 Q1
8 quarters
ENSG icon
13
The Ensign Group
ENSG
$10.4B
$13.4M 3.34%
357,028
-319,030
-47% -$14M
2017 Q4
9 quarters
HCA icon
14
HCA Healthcare
HCA
$101B
$9.07M 2.26%
+101,000
New +$13.1M
2020 Q1
0 quarters
MODN icon
15
DELISTED
MODEL N, INC.
MODN
$8.31M 2.07%
374,284
+166,669
+80% +$4.87M
2019 Q3
2 quarters
SNY icon
16
Sanofi
SNY
$96.5B
$8.29M 2.06%
189,578
-252,083
-57% -$12.1M
2017 Q4
9 quarters
FATE icon
17
Fate Therapeutics
FATE
$231M
$6.78M 1.69%
305,485
-55,171
-15% -$1.4M
2018 Q4
5 quarters
DXCM icon
18
DexCom
DXCM
$33.1B
$5.26M 1.31%
78,148
+29,948
+62% +$1.86M
2019 Q3
2 quarters
TARO icon
19
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$4.68M 1.16%
76,459
+71,506
+1,444% +$5.3M
2019 Q4
1 quarter
AMRN icon
20
CALL
Amarin Corp
AMRN
$244M
$4.09M 1.02%
51,180
+1,470
+3% +$488K
2019 Q3
2 quarters
KDMN
21
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.09M 1.02%
975,350
-166,589
-15% -$717K
2019 Q4
1 quarter
PNTG icon
22
Pennant Group
PNTG
$1.48B
$4M 0.99%
282,181
-89,012
-24% -$2.25M
2019 Q4
1 quarter
MNTA
23
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$3.99M 0.99%
+146,550
New +$4.08M
2020 Q1
0 quarters
RDUS icon
24
DELISTED
Radius Health, Inc.
RDUS
$3.91M 0.97%
301,073
-17,738
-6% -$316K
2017 Q4
9 quarters
XLRN
25
DELISTED
Acceleron Pharma
XLRN
$3.8M 0.95%
+42,305
New +$3.29M
2020 Q1
0 quarters
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Eversept Partners held 86 positions worth $402M, down 29% from $566M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners deployed $47.9M of net new capital in Q1 2020, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was HCA Healthcare: 101,000 shares worth $9.07M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was GSK, an estimated $21.9M trimmed.

  • Eversept Partners's largest Q1 2020 buy was HCA Healthcare: 101,000 shares worth $9.07M.
  • Eversept Partners added most to Zogenix, Inc. in Q1 2020, an estimated $55.3M increase.
  • Eversept Partners's biggest Q1 2020 reduction was GSK, cutting an estimated $21.9M.
  • Eversept Partners fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $18.3M.
  • Eversept Partners's ten largest holdings make up 63% of its $402M portfolio in Q1 2020.
  • Eversept Partners opened 14 new positions and closed 25 in Q1 2020.
  • Eversept Partners's portfolio value fell 29% quarter-over-quarter to $402M.

Based on Eversept Partners's 13F filing for Q1 2020, filed 13 May 2020.